Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|October 19, 2018
EMA Recommends Six Medicines for Approval
Author(s)Pharmaceutical Technology Editors
The recommended drugs include one biosimilar, two orphan medicines, and three extensions of therapeutic indication.
Advertisement
The European Medicines Agency (EMA)
CHMP recommended granting a marketing authorization for Takhzyro (lanadelumab), the first monoclonal antibody therapy for the prevention of recurrent attacks of hereditary angioedema (HAE), according to the agency. This medicine was reviewed under EMA's accelerated assessment procedure, reserved for medicines of major public health interest.
The committee recommended granting a marketing authorization for Namuscla (mexiletine hydrochloride), for the treatment of myotonia in adult patients with non-dystrophic myotonic disorders. EMA reports that Namuscla is the first treatment for this disease to be authorized European Union-wide. CHMP also recommended the granting of a marketing authorization for Bevespi Aerosphere (glycopyrronium/formoterol fumarate dihydrate) for maintenance treatment of chronic obstructive pulmonary disease.
Dengvaxia (dengue tetravalent vaccine (live, attenuated) was recommended for a marketing authorization. This is the first vaccine in the EU for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4 in people who are between 9 and 45 years old, live in an endemic area, and already had a prior dengue virus infection. The committee also adopted a positive opinion for Flucelvax Tetra (influenza vaccine surface antigen inactivated prepared in cell cultures) for the prevention of influenza in adults and children from nine years of age.
Biosimilar Ogivri (trastuzumab) received a positive opinion from the CHMP for the treatment of breast and gastric cancer. Extensions of indication for Kalydeco, Keytruda, and NovoSeven were also recommended.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5